Across TCGA pan-cancer cohorts, IGLV1-51 Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated IGLV1-51 data layer compared with 20 for mass-spec protein and 8 for mass-spec protein.

The strongest signal is observed in lung squamous cell carcinoma (LUSC), where higher IGLV1-51 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated IGLV1-51 expression acts as an unfavorable survival marker.

LUSC, STAD, and PRAD are the cancer types where IGLV1-51 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUSC	OS	Median	IV	0.001	0.673	.014	12	view →
STAD	OS	Median	II,III,IV	0.254	0.662	.011	6	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

Exploration

Same gene, other analysis: IGLV1-51 tumor-vs-normal RNA expression · all IGLV1-51 data types